Glaxosmithkline Pharmaceuticals Ltd
Glaxosmithkline Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
GSK India aims to deliver growth above the Indian Pharmaceutical Market (IPM) growth, projected at 8-9% for FY2026. GSK India aims to grow above the Indian Pharmaceutical Market (IPM) growth of 8-9% for FY2026.
From Glaxosmithkline Pharmaceuticals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- GSK India aims to deliver growth above the Indian Pharmaceutical Market (IPM) growth, projected at 8-9% for FY2026.
- The aspiration for double-digit growth remains firmly in place.
- Growth strategy is primarily volume-led, especially in the general medicines portfolio, with volume growth recorded at around 8% recently.
- Price hikes are considered a supplementary lever but not the main growth driver, mainly due to price controls on over half the portfolio.
- Specialty segments, including oncology and vaccines (e.g., Shingrix), are expected to contribute significantly to future growth.
- Investments continue in digital and omni-channel outreach to expand healthcare practitioner coverage, increasing touchpoints by over 40%.
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Glaxosmithkline Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is investing significantly in oncology market development, including recruitment of a new oncology business head and expanding the medical team.
- There is continued focus on accelerating the launch of innovative assets from the global pipeline, as evidenced by ongoing clinical trials (19 global trials in oncology, hepatology, etc.) and planned launches of oncology products like Zejula and Jemperli.
- Manufacturing capability is maintained and leveraged with a state-of-the-art facility in Nashik that supplies significant volumes and serves WHO programs.
- Emphasis remains on sustaining and improving margins while investing in new growth platforms such as vaccines (e.g., Shingrix) and specialty medicines.
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Glaxosmithkline Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Glaxosmithkline Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹995 Cr, net profit ₹278 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glaxosmithkline Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Glaxosmithkline Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Glaxosmithkline Pharmaceuticals Ltd Q4 FY25 results?
GSK India aims to deliver growth above the Indian Pharmaceutical Market (IPM) growth, projected at 8-9% for FY2026. GSK India aims to grow above the Indian Pharmaceutical Market (IPM) growth of 8-9% for FY2026.
What is Glaxosmithkline Pharmaceuticals Ltd share price analysis?
Glaxosmithkline Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 43.3 with a market cap of ₹45,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glaxosmithkline Pharmaceuticals Ltd planning capital expenditure?
The company is investing significantly in oncology market development, including recruitment of a new oncology business head and expanding the medical team.
Keep Glaxosmithkline Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.